硫胺衍生物的当前发展使中枢神经系统药物发现成为可能
Klaudia Blicharz-Futera1, Michał Kamiński1, Katarzyna Grychowska2
1Department of Organic Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, 9 Medyczna Street, 30-688 Krakow, Poland; Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College, 16 Łazarza Street, 31-530 Krakow, Poland.
Bioorganic chemistry
|January 31, 2025
概括
硫胺衍生物在治疗超出其抗菌用途的中枢神经系统 (CNS) 疾病方面表现有前途. 研究突出了它们作为新型中枢神经系统药物发现的酶/离子通道抑制剂和受体配体的潜力.
科学领域:
- 药用化学 医学化学
- 神经药理学神经药理学
- 药物发现 药物发现 药物发现
背景情况:
- 硫胺衍生物,最初以抗菌特性而闻名,已经扩大了治疗应用.
- 它们的实用性现在包括治疗中枢神经系统 (CNS) 疾病.
研究的目的:
- 审查具有显著中枢神经系统活性的主要硫胺基化合物.
- 讨论开发用于中枢神经系统疾病的硫胺的挑战和机遇.
主要方法:
- 对硫胺衍生物的临床前和临床数据的分析.
- 在动物模型和临床试验中检查结构-活性关系,ADMET特性和疗效.
主要成果:
- 识别了硫胺化合物,显示出显著的中枢神经系统活性.
- 详细介绍了这些药物的作用模式,治疗意义和药理学标.
结论:
- 阿里硫胺是中枢神经系统疾病中药物发现的多功能动机.
- 为开发针对中枢神经系统疾病的新型治疗剂提供多种机会.
更多相关视频
相关概念视频
Drug Metabolism: Phase II Reactions
3.5K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.5K
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Phase II Reactions: Sulfation and Conjugation with α-Amino Acids
155
Sulfation and α-amino acid conjugation are two critical biotransformation reactions in drug metabolism. Sulfation, a phase II biotransformation reaction, involves adding a polar sulfate group to a drug, enhancing its water solubility and promoting excretion. This process can either co-occur with or occur independently of glucuronidation. Nonmicrosomal sulfotransferase enzymes catalyze the process. The reaction involves 3'-phosphoadenosine-5'-phosphosulfate or PAPS coenzyme...
155
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
Preparation and Reactions of Sulfides
4.7K
Sulfides are the sulfur analog of ethers, just as thiols are the sulfur analog of alcohol. Like ethers, sulfides also consist of two hydrocarbon groups bonded to the central sulfur atom. Depending upon the type of groups present, sulfides can be symmetrical or asymmetrical. Symmetrical sulfides can be prepared via an SN2 reaction between 2 equivalents of an alkyl halide and one equivalent of sodium sulfide.
4.7K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
219
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
219


